Inhibition of prostate cancer by suicide gene targeting the FCY1 and HSV-TK genes

Oncol Rep. 2009 Dec;22(6):1341-7. doi: 10.3892/or_00000573.

Abstract

Prostate cancer is one of the most prevalent tumors. The switch of androgen signal dependence makes therapy more complex. Although reports on introduction of a single suicide gene exist, double suicide gene therapy has not been reported yet. In the current study, two suicide genes were constructed in the pIRES plasmid driven by PSMA promoter. 5-FC and GCV combination in vitro led to a higher growth inhibition on prostate cancer compared to a single pro-drug. Retarded xenograft tumor growth was observed in castrated nude mice after double suicide gene activation. Furthermore, decreased metastasis was observed with double suicide gene treatment. These findings suggest that specific double suicide gene strategy could be a potential option for the therapy of prostate cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Female
  • Genes, Transgenic, Suicide / genetics*
  • Genetic Therapy / methods*
  • HeLa Cells
  • Humans
  • Male
  • Models, Genetic
  • Neoplasm Metastasis
  • Promoter Regions, Genetic
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / therapy*
  • Simplexvirus / genetics*
  • Tetrazolium Salts / pharmacology
  • Thiazoles / pharmacology
  • Thymidine Kinase / genetics*
  • Treatment Outcome

Substances

  • Tetrazolium Salts
  • Thiazoles
  • Thymidine Kinase
  • thiazolyl blue